BioLineRx is a biotechnology business based in the US. BioLineRx shares (BLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.25 – an increase of 0.93% over the previous week. BioLineRx employs 28 staff and has a trailing 12-month revenue of around $28.9 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.25 |
|---|---|
| 52-week range | $2.30 - $35.60 |
| 50-day moving average | $3.12 |
| 200-day moving average | $13.68 |
| Wall St. target price | $33.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.44 from 2025-05-02
| 1 week (2025-04-28) | 8.01% |
|---|---|
| 1 month (2025-04-04) | 29.81% |
| 3 months (2025-02-06) | -1.43% |
| 6 months (2024-11-06) | 659.38% |
| 1 year (2024-05-06) | 378.91% |
|---|---|
| 2 years (2023-05-05) | -92.77% |
| 3 years (2022-05-05) | 50.8 |
| 5 years (2020-05-05) | 67.2 |
Valuing BioLineRx stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioLineRx's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioLineRx's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.2. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioLineRx's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $28.9 million |
|---|---|
| Gross profit TTM | $19.7 million |
| Return on assets TTM | -23.28% |
| Return on equity TTM | -69.11% |
| Profit margin | -31.86% |
| Book value | $0.01 |
| Market Capitalization | $12.8 million |
TTM: trailing 12 months
We're not expecting BioLineRx to pay a dividend over the next 12 months.
BioLineRx's shares were split on a 1:40 basis on 29 January 2025 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BioLineRx shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for BioLineRx shares which in turn could have impacted BioLineRx's share price.
Over the last 12 months, BioLineRx's shares have ranged in value from as little as $2.3001 up to $35.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioLineRx's is 0.946. This would suggest that BioLineRx's shares are less volatile than average (for this exchange).
BioLineRx Ltd. , a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .